<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Benralizumab Noninferior to Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis

Default sub title

minute read

by HealthDay | March 8, 2024
placeholder

For patients with eosinophilic granulomatosis with polyangiitis (EGPA) receiving standard care, benralizumab is noninferior to mepolizumab, according to a study published in the March 7 issue of the New England Journal of Medicine.

Topics: Press Coverage